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Summary
To further develop an integrated in vitro testing strategy for replacement of in vivo tests for (anti-)
estrogenicity testing, the ligand-modulated interaction of coregulators with estrogen receptor α  
was assessed using a PamChip® plate. The relative estrogenic potencies determined, based on ERα 
binding to coregulator peptides in the presence of ligands on the PamChip® plate, were compared to 
the relative estrogenic potencies as determined in the in vivo uterotrophic assay. The results show that 
the estrogenic potencies predicted by the 57 coactivators on the peptide microarray for 18 compounds 
that display a clear E2 dose-dependent response (goodness of fit of a logistic dose-response model of 
0.90 or higher) correlated very well with their in vivo potencies in the uterotrophic assay, i.e., coefficient 
of determination values for 30 coactivators higher than or equal to 0.85. Moreover, this coregulator 
binding assay is able to distinguish ER agonists from ER antagonists: profiles of selective estrogen 
receptor modulators, such as tamoxifen, were distinct from those of pure ER agonists, such as dienestrol. 
Combination of this coregulator binding assay with other types of in vitro assays, e.g., reporter gene assays 
and the H295R steroidogenesis assay, will frame an in vitro test panel for screening and prioritization of 
chemicals, thereby contributing to the reduction and ultimately the replacement of animal testing for  
(anti-)estrogenic effects.
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method
Received August 14, 2012; accepted in revised form January 2, 2013
Abbreviations
lBD ligand-binding domain
MIe molecular initiating event
NCOA1 nuclear receptor coactivator 1
NCOR1 nuclear receptor corepressor 1
NR nuclear receptor 
OMIY-bisphenol  4,4'-(octahydro-4,7-methano-5h- 
 inden-5-ylidene)bisphenol
R2	 coefficient	of	determination
ReACH Registration, evaluation, Authorization  
 and restriction of Chemicals
SeRMs selective estrogen receptor modulators
2,4,5-t 2,4,5-trichlorophenoxyacetic acid
CV	 coefficient	of	variation
DMSO dimethyl sulfoxide
E2	 17β-estradiol
EE2	 17α-ethinyl	estradiol
ePA environmental Protection Agency,  
 United States
eR estrogen receptor
GSt glutathione S-transferase
ICCVAM Interagency Coordinating Committee  
 on the Validation of Alternative Methods
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1  Introduction
estrogens exert their physiological effects mainly through activa-
tion of the estrogen receptor (eR) in target cells (Couse and Ko-
rach, 1999; Heldring et al., 2007). Although two main forms of 
ER	exist,	ERα	and	ERβ,	in	(reproduction)	toxicology	the	primary	
attention	goes	to	the	ERα,	as	it	is	the	dominating	type	in	breast	and	
uterus tissue (Gustafsson, 1999; Harris et al., 2002). Moreover, 
with	respect	to	regulatory	purposes,	the	focus	is	on	ERα	because	
binding	and	induction	of	ERα	is	implicated	as	a	key	molecular	
initiating event (MIe) in estrogenicity-related adverse endpoints. 
ERα	and	ERβ,	like	all	the	members	of	the	nuclear	receptor	(NR)	
super-family, are ligand-dependent transcription factors that 
work	in	concert	with	transcriptional	coregulators	to	control	tar-
get gene transcription. Upon ligand binding, the ligand-binding 
domain (lBD) undergoes a conformational change that leads to 
receptor dimerization, translocation of the eR from cytosol to 
nucleus, and binding to estrogen-responsive elements. Moreover, 
as a result of the intramolecular conformational changes induced 
by	ligand	binding,	the	affinity	of	the	ER	for	coregulator	proteins	
is changed, resulting in recruitment or release of transcriptional 
coactivator or corepressor proteins, respectively, that enhance 
or repress the interaction of RNA polymerase II with estrogen-
responsive gene promoters and all of the subsequent reactions 
needed to actually induce or repress transcription of target genes 
(Klinge, 2000; Ascenzi et al., 2006).
In general, the transcriptional coregulator family consists 
of coactivators, which augment the activity of the receptors, 
and corepressors that mediate the repressive effects of recep-
tors	(Johnson	and	O̓Malley,	2012;	McKenna	et	al.,	1999).	The	
most	studied	group	of	ERα	coactivators	includes	the	p160	pro-
tein family, consisting of NCOA1 (SRC-1), NCOA2 (SRC-2), 
and NCOA3 (SRC-3), which interact with the activation func-
tion-2 (AF-2) domain of agonist-bound eRs through multiple 
lxxll motifs present in these coactivator proteins (where l 
is leucine and x is any amino acid) (Klinge, 2000; Metzler et 
al., 2001). Structural analysis of nuclear receptor (NR) lBDs 
has established that agonist binding stabilizes the AF-2 helix in 
an	active	conformation	to	form	a	charge	clamp	pocket,	which	
is permissive for interactions with lxxll motifs. In contrast, 
eR antagonists affect the positioning of the AF-2’s mobile C-
terminal	 helix	 (helix	 12)	 to	 form	 a	 large	 binding	 pocket	 that	
interacts with the lxxxIxxxl motifs of corepressor proteins 
(where I is isoleucine) such as nuclear receptor corepressor 1 
(NCOR1) and nuclear receptor corepressor 2 (NCOR2), thereby 
disrupting the lxxll-binding site and preventing coactivator 
recruitment	(Shiau	et	al.,	1998;	Brzozowski	et	al.,	1997;	Kong	
et al., 2005).
the standard test for disruption of normal estrogen function is 
the in vivo uterotrophic assay, i.e., a test with immature or ova-
riectomized rodents using uterus weight as the crucial read-out 
parameter (Clode, 2006; Owens and Ashby, 2002). With a view 
to the ReACH Regulation (eC, 2006) and the need to reduce, 
refine,	 and	 replace	 the	 use	 of	 experimental	 animals	 for	 safety	
testing (3Rs), modulation of eR activity is usually quantitatively 
analyzed by assaying eR binding, eR-controlled reporter genes, 
or other downstream events such as estrogen receptor-mediated 
cell	proliferation	(Bovee	and	Pikkemaat,	2009).	ER	binding	as-
says	are	rapid	and	easy	to	perform;	one	of	the	main	drawbacks,	
however, is that these assays are unable to distinguish receptor 
agonists from receptor antagonists. Moreover, the rat uterine 
cytosol eR binding assay, currently listed as part of the envi-
ronmental Protection Agency’s (ePA) endocrine Disruptor 
Screening Program tier 1 screening battery, still requires the use 
of	animals	as	a	source	of	ERs.	Unlike	receptor	binding	assays,	
reporter gene assays can distinguish between agonist and an-
tagonist activity. Several reporter gene assays have been devel-
oped and applied as screening tools to determine the estrogenic/
anti-estrogenic activities of compounds, as they are cheap, fast, 
robust, and have been shown to produce relevant and reliable 
outcomes (Bovee et al., 2009; van der Burg et al., 2010; Plotan et 
al., 2012). Proliferation assays and low-density DNA microchip-
based	analysis	of	marker	gene	expression	also	have	been	shown	
to provide valuable tools for estrogenicity testing, and outcomes 
correlate well with the in vivo uterotrophic assay (Wang et al., 
2012, 2013), but these two assays are laborious and require 3-6 
days. therefore, they are not ideal for the large-scale testing of 
chemicals with respect to initiatives such as ReACH. 
thus far, studying nuclear receptor interactions with coregu-
lators has been performed mainly for theoretical reasons and 
for	drug	development	(Lonard	and	O̓Malley,	2012;	Hsia	et	al.,	
2010; McDonnell and Wardell, 2010). However, a high-through-
put in vitro	assay	enabling	quantification	of	coactivator	or	core-
pressor recruitment by receptors upon ligand binding would 
have the potential to add relevant information to an integrated in 
vitro strategy for (anti-)estrogenicity testing, aiming at prioriti-
zation of chemicals and reduction of in vivo animal experiments 
needed for initiatives such as ReACH. In the present study, the 
ligand-modulated	interaction	of	coregulators	with	ERα	was	as-
sessed using a PamChip® plate consisting of 96 identical arrays, 
each array containing 155 immobilized nuclear receptor (NR) 
coregulator peptides harboring either lxxll (coactivator) or 
lxxxIxxxl (corepressor) motifs. A set of 23 reference com-
pounds was tested in the coregulator binding assay based on the 
PamChip® plate. twenty-one of these compounds were selected 
from the 78 compounds listed by the Interagency Coordinating 
Committee on the Validation of Alternative Methods (ICCVAM) 
for validation of in vitro eR binding and transcriptional activa-
tion assays assays (ICCVAM, 2003). the objective was to de-
termine to what extent this coregulator binding assay correctly 
predicts the estrogenic/anti-estrogenic activities and potencies of 
the test compounds when compared to the outcomes obtained in 
the in vivo uterotrophic assay.
2  Materials and methods
Chemicals
17β-Estradiol	 (E2),	 diethylstilbestrol,	 meso-hexestrol,	 cou-
mestrol, dienestrol, zearalenone, corticosterone, tamoxifen, 
4-hydroxytamoxifen, bisphenol A, ethyl paraben, o,p’-DDt, 
p-n-nonylphenol, and apigenin were obtained from Sig-
ma-Aldrich Chemie B.V. (Zwijndrecht, the Netherlands). 
17α-Ethinyl	 estradiol	 (EE2),	 progesterone,	 and	 testosterone	
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ing. ligand dose-response relations were analyzed using the 
DRC	 package	 in	 R	 (version	 2.12.0,	 http://www.r-project.org).	
A	sigmoidal	4-parameter	 logistic	model	was	fitted	 to	 the	dose-
response	data	and	the	goodness-of-fit	parameter	and	EC50 values 
as	calculated	by	the	DRC	package	were	recorded.	Relative	bind-
ing potency (RBP) values were obtained from the ratio of the 
concentration	 of	E2	 needed	 to	 achieve	 50%	of	maximal	ERα-
lBD binding to the coregulator and the concentration of the test 
compounds required to achieve a similar effect. this ratio subse-
quently is multiplied by 100. the RBP value of e2 is thus 100, 
resulting in a logRBP of 2.0. A cut-off value of -5.0 is listed for 
compounds showing no effect. the estrogenicity data used for 
comparisons	with	the	current	ERα-coregulator	binding	data	were	
eR binding data in the review published by ICCVAM (2003), 
and the BG1luc eR tA data reported by the National toxicology 
Program (NtP) Interagency Center for the evaluation of Alterna-
tive toxicological Methods (NICeAtM) and ICCVAM (2011). 
For comparison of the presented in vitro	ERα-coregulator	bind-
ing data with estrogenicity in vivo, uterotrophic assay data were 
used that were derived from the endocrine Disruptor Knowledge 
Base (eDKB), designed and produced by the National Center for 
toxicological Research, USA (Ding et al., 2010).
3  Results
twenty-one of the 23 compounds tested were selected from the 
78 compounds listed by ICCVAM for validation of in vitro eR 
binding and transcriptional activation assays, representing the 
main groups of compounds with estrogenic activity, i.e., natural 
steroids,	synthetic	steroids,	flavonoids,	phenols,	organochlorines,	
and phthalates (ICCVAM, 2003). Figure 1B shows the dose-re-
sponse	curves	of	ERα-LBD	binding	to	the	155	coregulator	pep-
tides	 as	 induced	by	17β-estradiol	 (E2).	Most	of	 the	 coregulator	
spots showed an increased binding signal with increasing e2 
concentrations, e.g., NCOA1_677_700, NCOA2_628_651 and 
NCOA3_673_695, which all have the lxxll motif signature 
sequence	 and	 are	 known	 to	 function	 as	 coactivators.	As	 an	 ex-
ample,	the	E2-induced	dose-response	curve	of	ERα-LBD	binding	
to coactivator peptide NCOA1_677_700 is shown in Figure 1C. 
the lowest concentration of the potent e2 that resulted in a de-
tectable	binding	of	ERα-LBD	to	NCOA1_677_700	was	0.19	nM,	
reaching a half maximal binding level (eC50) at approximately 
0.7 nM and binding was saturated above 20 nM. However, not 
all the coactivator peptides immobilized on the peptide microar-
ray showed an e2 concentration-dependent binding response of 
ERα-LBD,	 e.g.,	 chromodomain-helicase-DNA-binding	 protein	 
9 (CHD9_855_877) and centromere protein R (CeNPR_1_18) did 
not show any e2-induced binding. As expected, the corepressor 
peptides with the lxxxIxxxl motif, e.g., NCOR1_1925_1946 
and	NCOR2_2330_2352,	did	not	show	an	ERα-LBD	binding	re-
sponse upon co-incubation with e2. e2 was used as a reference 
compound on each of the two PamChip® plates. to assess the 
reproducibility of the assay, all duplicate e2 data together were 
plotted against each other, which resulted in a correlation with 
coefficient	of	determination	(R2)	of	0.944.	Moreover,	the	coeffi-
cient of variation (CV) was calculated at a binding-saturating e2 
(t) were purchased from Steraloids (Newport, RI, USA), 
while genistein was obtained from Apin Chemicals (Abingdon, 
Oxon, UK). 4,4'-(Octahydro-4,7-methano-5h-inden-5-ylidene)
bisphenol (OMIY-bisphenol) was from Acros Organics (Fisher 
emergo B.V., landsmeer, the Netherlands). Dimethyl sulfox-
ide	(DMSO)	was	purchased	from	Merck	(Darmstadt,	Germany).	
Kepone and 2,4,5-trichlorophenoxyacetic acid (2,4,5-t) were 
obtained from Dr. ehrenstorfer GmbH (Augsburg, Germany). 
Butylbenzyl phthalate and di-n-butyl phthalate were purchased 
from tCI europe N.V. (Zwijndrecht, Belgium).
Nuclear receptor-coregulator interaction profiling
Ligand-modulated	interaction	of	coregulators	with	ERα-LBD	was	
assessed using a PamChip® plate described previously (Houtman 
et al., 2012). the PamChip® plate consists of 96 identical arrays, 
each array containing 155 NR coregulator peptides harboring ei-
ther lxxll (coactivator) or lxxxIxxxl (corepressor) motifs 
(PamGene International B.V., ’s-Hertogenbosch, the Netherlands). 
the coregulator peptides are immobilized on a porous metal oxide 
carrier	by	piezo	 technology	as	previously	used	 in	kinase	assays	
(Hilhorst et al., 2009; lemeer et al., 2007). the PamChip® plate 
was used in combination with the glutathione S-transferase (GSt)-
labeled	ERα-LBD	 to	 screen	dilution	 series	of	a	 set	of	23	com-
pounds. the peptide microarray was incubated with the test solu-
tion	containing	ERα-LBD-GST	in	the	absence	or	presence	of	ligand	
by pumping the sample up and down the three-dimensional metal 
oxide carrier (Fig. 1A). In short, assay mixtures were prepared on 
ice	in	a	master	96-well	plate	with	5	nM	GST-tagged	human	ERα-
lBD (PamGene International B.V.), 25 nM Alexa 488-conjugated 
GSt antibody (Invitrogen, Breda, the Netherlands), and ligand 
at the indicated concentration in reaction buffer (20 mM tris, pH 
7.5, 500 mM NaCl, 0.2% BSA, 0.05% tween-20). All assays were 
performed in a fully automated PamStation®-96 (PamGene Inter-
national B.V.) at 20°C applying two cycles per minute. the initial 
blocking	was	carried	out	by	incubating	each	array	for	20	cycles	with	
25	µl	blocking	buffer	(TBS	with	1%	BSA,	0.01%	Tween-20,	and	 
0.3%	skimmed	milk	powder).	Subsequently,	the	blocking	buffer	
was removed and 25 µl assay mix was transferred to each ar-
ray and incubated for 80 cycles (~40 min). eight concentra-
tions with tenfold serial dilution in dimethyl sulfoxide (DM-
SO;	 final	 concentration	 2%)	 of	 each	 compound	 were	 tested	
in singular. After removal of the unbound receptor by washing 
the plate with 25 µl tBS, tiff images were obtained by a CCD 
camera-based optical system integrated in the PamStation®- 
96 instrument. the total set of compounds was tested over two 
PamChip® plates and by using e2 as a reference compound on 
each plate.
Data analysis
Image analysis was performed using BioNavigator software 
(PamGene International B.V.), which performs automated array 
grid	 finding	 and	 subsequent	 quantification	 of	 signal	 and	 local	
background	 for	 each	 individual	 peptide.	 In	 short,	 the	 bounda-
ries	of	a	spot	are	determined	and	the	median	fluorescent	signal	
is	quantified	within	the	spot	(signal)	as	well	as	that	in	a	defined	
area	surrounding	it	(background).	The	signal-minus-background	
value is used subsequently as the quantitative parameter of bind-
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Fig. 1: Analysis of ERα-LBD binding to coregulators induced by 17β-estradiol
A. Schematic overview of the PamChip peptide microarray technology. B. Dose-response curves for ERα-LBD binding to the 155 
coregulator-derived receptor binding motifs induced by 17β-estradiol. C. Enlargement of the dose-response curve for 17β-estradiol-
induced binding of ERα-LBD to coactivator NCOA1_677_700.
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resulting	in	curve	fittings	with	a	goodness	of	fit	of	0.94,	0.78	
and 0.63, respectively for e2. the relative coregulator binding 
potency (RBP) values of these 23 compounds were calculated 
for these three coactivator peptides and listed in table 1. to 
allow comparison with the observed in vivo effects, the me-
dian log relative potency (logRP) of these compounds as de-
termined previously in the in vivo uterotrophic assay with mice 
or rats are included and shown in table 1. Figure 4 shows the 
comparison between the logRP values as determined in the in 
vivo uterotrophic assay and the logRBP values as determined 
in the coregulator binding assay based on coactivators of 
NCOA1_677_700, NRIP1_173_195, and PNRC2_118_139. 
Although tamoxifen had a clear effect on the binding of these 
three coactivators, its effect is mostly opposite to that of e2. 
As tamoxifen is a SeRM that mainly shows its antagonistic 
properties when tested on the current coregulator binding assay 
(Fig. 2), it is not possible to compare its observed antagonis-
tic binding effects with the agonistic binding effects obtained 
with e2. the same is valid for the SeRMs 4-hydroxytamoxifen 
and OMIY-bisphenol, which also show antagonistic coregu-
lator binding effects. therefore, for the comparison of the in 
concentration (20 nM) over each pair of duplicate e2 data. this 
resulted in a median intraplate CV of 8.0%.
All	 known	 estrogenic	 compounds	 tested	 on	 the	 peptide	
microarray (e.g., ee2, dienestrol, diethylstilbestrol, and meso-
hexestrol)	resulted	in	coregulator	binding	profiles	similar	to	that	
of e2. except for testosterone, the negative controls (i.e., corti-
costerone	and	progesterone)	showed	no	statistically	significant	
binding changes compared with the solvent control DMSO (da-
ta not shown), while the selective estrogen receptor modulators 
(SeRMs), i.e., tamoxifen, 4-hydroxytamoxifen, and (OMIY-
bisphenol), showed a completely different coregulator bind-
ing	profile.	As	shown	in	Figure	2,	compared	with	the	solvent	
control	 DMSO	 and	 the	 known	 estrogen	 agonists,	 tamoxifen	
strongly	inhibited	binding	of	ERα-LBD	to	almost	all	coactiva-
tor peptides, and similar repression of binding was observed 
with 4-hydroxytamoxifen and OMIY-bisphenol (see supple-
mentary	files	1	and	2	at	www.altex-edition.org).	Surprisingly,	
no binding was observed for these SeRMs to the corepressors 
present on the peptide microarray. Figure 3 shows the dose-
response curves of 23 compounds based on three coregulators 
NCOA1_677_700, NRIP1_173_195, and PNRC2_118_139, 
Fig. 2: Analysis of ERα-LBD binding to coregulators induced by tamoxifen
Wang et al.
Altex 30, 2/13150
data available in the literature, and although apigenin has been 
shown to display estrogenic activities in in vitro reporter gene 
assays (Willemsen et al., 2004; long et al., 2008), it was nega-
tive for estrogenic effects on the uterus in the uterotrophic as-
say. However, this is probably due to the poor bioavailability of 
apigenin in rodents (Breinholt et al., 2000). In the coregulator 
binding	assay	apigenin	clearly	 induced	binding	of	ERα-LBD	
to similar coactivators as e2. Figure 4 illustrates that using 
all dose-response curves and corresponding coregulator bind-
ing potencies (logRBP), the NCOA1_677_700 coactivator 
peptide-based logRBP values correlated very well with the in 
vivo relative potencies (logRP), values determined in the utero-
trophic assay (R2=0.89, p < 0.0001, n=18). Binding of coacti-
vator NRIP1_173_195, with an intermediate e2 dose-response 
vitro coregulator binding assay with the in vivo uterotrophic 
assay, tamoxifen, 4-hydroxytamoxifen, and OMIY-bisphenol 
were left out (Fig. 4 and tab. 2). Instead, to provide an overall 
measure of the antagonistic binding potency for the SeRMs, 
the median of the IC50 values were calculated over all those 
coregulators	showing	a	good	fit	of	the	standard	dose-response	
model	used	(goodness-of-fit	of	a	sigmoidal	4-parameter	logistic	
model of 0.85 or higher). the number of coregulators meeting 
this requirement are 29 for OMIY-bisphenol, 41 for tamoxifen 
and 50 for 4-hydroxytamoxifen, resulting in median IC50 of 
1.39×10-7 M, 2.55×10-7 M, and 1.82×10-9 M, respectively. In 
addition to the SeRMs, apigenin and 2,4,5-t also were left out 
for the comparison of the coregulator binding assay with the in 
vivo uterotrophic assay. For 2,4,5-t there are no uterotrophic 
Fig. 3: Dose-response curves of ERα-LBD binding to the NCOA1_677_700, NRIP1_173_195, and PNRC2_118_139 coactivator 
peptides for the 23 compounds
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4  Discussion
the aim of the present study was to investigate the potential 
of the PamChip® plate based coregulator binding assay as part 
of an integrated in vitro testing strategy for detection of (anti-)
estrogenic activity. to this end a set of 23 reference compounds 
was investigated using the peptide microarray in combination 
with	the	GST-labeled	ligand-binding	domain	of	ERα.	As	a	con-
centration series consisting of eight concentrations with tenfold 
serial dilution was tested for each compound, the dose-response 
relation could be determined with great statistical accuracy as 
demonstrated	by	the	goodness	of	fit	data.	With	a	median	EC50 
of	 0.9	 nM,	 an	 intraplate	 coefficient	 of	 variation	 of	 8.0%	 at	 a	
saturating binding concentration of 20 nM e2, and an excellent 
correlation (R2=0.944) between duplicate e2 measurements, the 
sensitivity and reproducibility of the coregulator binding assay 
was well within the range observed for other commonly used 
in vitro eR functional assays. Moreover, the coregulator bind-
ing	assay	uses	fluorescence	as	an	endpoint	measurement,	which	
offers several advantages in comparison to radioligand receptor 
binding assays, such as low costs and avoiding problems related 
to health hazards of radiation exposure and radioactive waste 
disposal.	Dose-response	analysis	of	 the	binding	of	ERα-LBD	
to coregulators in the presence of the ligand showed that the 
known	estrogens	 (e.g.,	EE2,	 dienestrol,	 diethylstilbestrol,	 and	
meso-hexestrol)	resulted	in	coregulator	binding	profiles	similar	
to the reference compound e2, but each compound showed its 
own	specific	potency	resulting	in	different	EC50 values. except 
for testosterone, the negative controls (i.e., corticosterone and 
progesterone)	 showed	 no	 significant	 binding	 changes	 com-
pared with the solvent control DMSO. the SeRMs tested on 
the peptide microarray (i.e., tamoxifen, 4-hydroxytamoxifen, 
and OMIY-bisphenol) showed no binding on the corepressors 
present on the peptide microarray and showed decreased coac-
curve	goodness	of	fit	of	0.78,	still	resulted	in	a	relatively	good	
correlation (R2=0.79, p < 0.0001, n=18), whereas the binding 
of PNRC2_118_139, which has a relatively low e2 dose-re-
sponse	 curve	 goodness	 of	 fit	 of	 0.63,	 showed	 no	 correlation	
with the in vivo determined logRP values of the uterotrophic 
assay (R2=0.01, p =0.698, n=18). 
Next,	the	dose-response	curve	goodness-of-fit	value	for	each	
coregulator of each compound was calculated. Out of the 155 
coactivator	peptides,	57	gave	E2	curve	fittings	higher	 than	or	
equal to 0.9. the determined eC50 values for e2 derived from 
these 57 curves were all in the low nanomolar range and showed 
a median eC50 of 0.9 nM. Subsequently, similar to what is 
shown in table 1 and Figure 4, the logRBP values based on 
these 57 coactivators were calculated for each compound and 
correlated with different relative potency values from literature, 
i.e., logRBA values obtained in the eR binding assay (n=19), 
logReP values obtained in the BG1luc eR transcriptional ac-
tivation assay (n=16), and logRP values obtained in the utero-
trophic assay (n=18). the resulting R2 values are shown in 
table 2. In general, the estrogenic potencies predicted by the 
coregulator binding assay correlated well with the eR binding 
assay, as well as with the BG1luc eR transcriptional activation 
assay, which was recently approved by OeCD as a test method 
for identifying estrogen receptor agonists and antagonists. As 
shown in table 2, 33 coactivators showed an R2 value higher 
than or equal to 0.80 with the eR binding assay, and 32 coac-
tivators showed an R2 value higher than or equal to 0.80 with 
the BG1luc eR transcriptional activation assay. For the cor-
relation with the in vivo uterotrophic assay, in total 48 coac-
tivators showed an R2 value higher than or equal to 0.8, and 
among these, 30 coactivators showed an R2 value higher than or 
equal to 0.85 (e.g., NCOA1_677_700, NCOA3_673_695, and 
NR0B2_106_128).	A	low	correlation	coefficient	was	observed	
for Bl1S1_1_11 (R2=0.49).
Fig. 4: Comparison of the log relative potencies (logRP) measured in the in vivo uterotrophic assay with  
the log relative coregulator binding potency (logRBP) as determined in the coregulator binding assay for the NCOA1_677_700, 
NRIP1_173_195, and PNRC2_118_139 coactivator peptides for the 18 compounds
Tamoxifen, 4-hydroxytamoxifen, OMIY-bisphenol, apigenin and 2,4,5-T were excluded from the comparison.
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Tab. 1: Comparison of the relative potencies obtained in the ER binding assay, BG1Luc ER transcriptional activation assay,  
and in vivo uterotrophic assay with those obtained in the coregulator binding assay for the 23 compounds
Compounds  CAS nr. ER binding BG1Luc  Uterotrophic  Coregulator binding assay 
   assay ER TA assay  logRBPh 
   log RBAa logREPe logRPf   
      NCOA1_ NRIP1_ PNRC2_ 
      677_700 173_195 118_139
Steroids 17β-Estradiol  50-28-2 2.0 2.0 2.0 2.0 2.0 2.0
and synthetic
 17α-Ethinyl  57-63-6 2.2 1.7 3.0 2.0 2.2 -5.0 estrogens estradiol 
 Diethylstilbestrol 56-53-1 2.1 1.2 2.7 1.6 2.4 -5.0
 Dienestrol 84-17-3 2.0b NA 2.4 1.6 1.9 -5.0
 meso-Hexestrol 84-16-2 2.4 1.3 2.5 2.0 2.0 -5.0
 Corticosterone  50-22-6 -5.0c -5.0 -5.0 -5.0 -5.0 -5.0
 Progesterone  57-83-0 -3.5 -5.0 -5.0 -5.0 -5.0 -5.0
 Testosterone 58-22-0 -1.6 -3.2 -5.0 -3.0 -2.5 0.7
Phytoestrogens Coumestrol   479-13-0 1.1 -2.6 -0.8 -0.7 -2.1 -5.0
(natural products)
 Genistein  446-72-0 0.2 -2.9 -2.7 -0.1 -0.1 -5.0
 Apigenin 520-36-5 0.1 -3.6 -5.0 -1.3 -3.8 -5.0
 Zearalenone  17924-92-4 1.2 NA -0.7 0.5 -5.0 -5.0
Phenols OMIY-bisphenol  1943-97-1 NAd NA -0.3g - - -
 p-n-Nonylphenol 104-40-5 -1.5  NA -5.0 -5.0 -5.0 -5.0
 Bisphenol A 80-05-7 -1.5 -3.1 -1.6 -2.6 -3.2 -5.0
Organochlorines Kepone 143-50-0 -1.5 -3.2 -1.0 -1.7 -0.7 -5.0
 o,p’-DDT  789-02-6 -1.7 -3.1 -3.5 -5.0 -5.0 -5.0
 2,4,5-T 93-76-5 -5.0 NA NA -5.0 -5.0 -5.0
Phthalates Butylbenzyl 85-68-7 -2.7 -3.8 -5.0 -5.0 -5.0 -5.0 
 phthalate 
 Di-n-butyl 84-74-2 -2.6 -2.6 -5.0 -5.0 -5.0 -5.0 
 phthalate 
Paraben  Ethyl paraben  120-47-8 -3.2 -4.9 -5.0 -5.0 -5.0 1.9
SERMs Tamoxifen  10540-29-1 0.6 NA 1.0 - - -
 4-Hydroxy-  68047-06-3 2.2 NA 1.0 - - - 
 tamoxifen 
a Logarithm of the median ER relative binding affinity values listed in the review of ICCVAM (ICCVAM, 2003).
b Median logRBA value derived from the EDKB (National Center for Toxicological Research, USA) (Ding et al., 2010).
c A cut-off value of -5.0 is listed for compounds showing no effect.
d Data not available  
e Relative estrogenic potency is defined as the ratio between the EC50 of 17β-estradiol and the EC50 of the compound, and this ratio is 
subsequently multiplied by 100, calculated based on the BG1Luc ER TA data reported by ICCVAM (ICCVAM, 2011). The REP value of 
17β-estradiol is thus 100, resulting in a logREP of 2.0.
f  Median relative potency values based on uterotrophic assay in mouse or rat, derived from the EDKB (NCTR, USA). 17β-Estradiol is 
used as a reference chemical and is defined to have a relative potency of 100 (logRP=2.0) (Ding et al., 2010). 
g LogRP of 4,4′-(octahydro-4,7-methano-5H-inden-5-ylidene)bisphenol was calculated based on the minimal active dose described by 
Yamasaki et al. (2003).
h Relative binding potency values are obtained from the ratio of the concentration of 17β-estradiol needed to achieve 50% of maximal 
binding of ERα-LBD to coregulator and the concentration of the test compounds required to achieve a similar effect, and this ratio is 
subsequently multiplied by 100. The RBP value of 17β-estradiol is thus 100, resulting in a logRBP of 2.0. 
i Compound showing only antagonist binding effect; therefore, the logRBP value cannot be determined.
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also	shown	to	elicit	weak	responses	at	very	high	concentrations	
(Bovee	 et	 al.,	 2004),	 once	 again	 confirming	 that	T	 is	 able	 to	
activate	the	ERα	in vitro.
the environmental pollutant p-n-nonylphenol (CAS nr.104-
40-5) was included by ICCVAM as a positive control in a set 
of reference compounds for validation of in vitro eR binding 
and transcriptional activation assays (ICCVAM, 2003). In our 
coregulator binding assay, this compound did not show any 
response. However, although others reported p-n-nonylphenol 
to be active in transcriptional activation assays based on either 
yeast cells or mammalian cells (Gaido et al., 1997; legler et 
al., 1999), a thorough review of these studies showed that a 
technical	mixture	like	the	one	available	from	Fluka	(approxi-
mately 85-92.7% of branched isomers) or p-nonylphenol (CAS 
No. 84852-15-3) was used instead of the unbranched nonyl 
chain (CAS nr.104-40-5). thus, the ICCVAM report may need 
to be updated in this regard. Meanwhile, it has been shown 
that the p-n-nonylphenol (CAS nr.104-40-5) was inactive in 
a yeast estrogen bioassay, while a technical mixture of nonyl-
phenol	from	Fluka	was	active	 in	 the	estrogen	yeast	bioassay	
(Bovee et al., 2004). From this, it could be concluded that 
p-n-nonylphenol is not estrogenic and that the estrogenicity of 
the technical mixture is due to one or more isomers with a 
branched side-chain. A similar conclusion was presented by 
Pedersen et al. (1999) studying the induction of plasma vitel-
logenin in rainbow trout by linear and technical nonyl- and 
octylphenol. In a more recent study, p-n-nonylphenol was even 
used as a negative control for the validation of a recombinant 
yeast estrogen receptor agonist assay (Kolle et al., 2010). 
Moreover, butylbenzyl phthalate, di-n-butyl phthalate, and 
ethyl	paraben	were	reported	to	bind	weakly	to	the	ER	and	were	
also slightly active in the BG1luc eR transcriptional activa-
tion assay (ICCVAM, 2003, 2011). In the coregulator binding 
assay,	although	they	may	also	bind	weakly	to	the	ERα-LBD,	
detectable coregulator recruitment was not induced by these 
compounds under the concentrations tested. In the in vivo uter-
otrophic assay, butylbenzyl phthalate, di-n-butyl phthalate and 
ethyl paraben also are not able to induce uterotrophic effects 
(Zacharewski	et	al.,	1998;	Sik	Kim	et	al.,	2005;	Hossaini	et	al.,	
2000). this demonstrated that the human cancer cell line based 
reporter gene assays are more sensitive than both the in vivo 
uterotrophic assay and the current coregulator binding assay, 
which is an advantage for screening estrogenicity in food or 
environmental samples. However, for prioritization and testing 
pure chemicals, all these in vitro assays are sensitive enough to 
measure	potent	to	weak	estrogens.	Compounds	that	are	nega-
tive in the coregulator binding assay, although slightly active 
in the BG1luc eR assay, may not have the highest priority to 
be further tested for estrogenicity in the in vivo uterotrophic 
assay. In addition, o,p’-DDt is able to induce a uterotrophic 
effect in the rat (Shelby et al., 1996; Newbold et al., 2001), 
but did not show an effect in the current coregulator binding 
assay. this is probably due to the narrow concentration range 
tested	 (20	 pM-200	 µM),	 resulting	 in	 poor	 fitting	 of	 the	 ap-
plied dose-response model to the data, and as a consequence, 
classification	of	 the	 response	of	o,p’-DDt as negative. With 
excellent correlation with the estrogen receptor binding as-
tivator	 binding	 signals	 compared	 to	 the	 known	 ER	 agonists	
and	 the	 solvent	 control	DMSO.	The	binding	profiles	of	 these	
SeRMs are thus unique, as they are almost opposite to the pro-
files	obtained	with	 the	known	ER	agonists	and	different	 from	
the	profiles	obtained	with	the	negative	controls	and	DMSO	sol-
vent control, indicating that the antagonistic properties of these 
SERMs	mainly	result	from	blocking	the	interaction	of	ERα	with	
coactivator peptides rather than recruitment of corepressors. 
These	findings	are	in	agreement	with	other	studies,	showing	that	
tamoxifen and 4-hydroxytamoxifen bind to the ligand-binding 
domain	of	ERα	and	cause	a	conformational	shift	of	helix	12	into	
an	adjacent	coactivator	site,	which	in	turn	prevents	ERα	from	
binding a coactivator (Shiau et al., 1998; Klinge et al., 2001; 
Pike	et	al.,	1999;	Konge	et	al.,	2005;	Kojetin	et	al.,	2008).	More-
over, the calculated IC50 values, based on all the coregulators 
showing	a	very	good	fit	of	 the	standard	dose-response	model,	
were 2.55×10-7 M and 1.82×10-9 M for tamoxifen and 4-hy-
droxytamoxifen, respectively. these IC50 values are also in line 
with data reported by ICCVAM, i.e., 7.12×10-7 M and 4.94×10-9 
M for tamoxifen and 4-hydroxytamoxifen, respectively, in the 
BG1luc eR transcriptional activation assay, demonstrating that 
the coregulator binding assay also is useful to test anti-estro-
genic properties of compounds. Although tamoxifen and 4-hy-
droxytamoxifen are mainly reported to act as eR antagonists in 
breast and as eR agonists in uterus tissue (Shang and Brown, 
2002), they are also able to inhibit the effect caused by ee2 in 
the uterotrophic assay and to induce breast cell proliferation in 
the	E-screen	 (Fang	 et	 al.,	 2000;	Yamasaki	 et	 al.,	 2003;	Wang	
et al., 2012). the OMIY-bisphenol shows both agonistic and 
antagonistic effects in the uterotrophic assay, and when tested 
in proliferation assays it also behaves as an agonist and antago-
nist,	demonstrating	a	biological	effect	profile	nearly	identical	to	
tamoxifen (Wang et al., 2012). thus, transcriptional activation 
assays, cell proliferation assays, and the in vivo uterotrophic 
assay are capable of displaying both the eR agonistic and eR 
antagonistic properties of tamoxifen, 4-hydroxytamoxifen, and 
OMIY-bisphenol. However, when tested on the peptide micro-
array, these three compounds showed only antagonistic effects. 
It	 is	 highly	unlikely	 that	 the	profiles	will	 reveal	 the	 agonistic	
properties of these SeRMs when co-exposed with e2 or ee2. 
the androgen testosterone (t) was used as a negative control, 
as it is inactive in the in vivo uterotrophic assay. In the coregula-
tor	binding	assay,	T	clearly	induced	the	binding	of	ERα-LBD	
to several coactivators (e.g., binding of NCOA1_677_700 re-
sulted a logRBP value of -3.0). However, in several studies it 
was shown that t can induce cell proliferation in MCF-7/BOS 
cells (e-screen), and it has been demonstrated that this atypical 
response	was	mediated	by	activation	of	the	ER.	More	specifi-
cally, the proliferative response induced by testosterone in the 
E-screen	 is	 partially	 due	 to	 its	 conversion	 into	 17β-estradiol	
by aromatase (Wang et al., 2012), partially due to formation of 
other estrogenic metabolites (Wang et al., 2013), and also par-
tially	due	to	T,	i.e.,	activation	of	ERα.	These	findings	are	in	line	
with the observations in the present study, i.e., t is capable of 
activating	ERα-LBD	and	induces	subsequent	binding	of	several	
coactivators. Moreover, when tested in a yeast estrogen bioassay 
lacking	steroid	metabolism	and	steroidogenesis	enzymes	T	was	
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Tab. 2: Correlation of the relative potencies obtained in the ER binding assay, BG1Luc ER transcriptional activation  
assay, and in vivo uterotrophic assay with those obtained in the coregulator binding assay based on 57 coactivators  
showing a clear sigmoidal dose-response relation for 17β-estradiol-induced binding of ERα-LBD as reflected by a  
goodness-of-fit value of 0.9 or higher
Coregulator binding assay Peptide IDa Motif  Uniprot Accession  Coefficient of determination (R2)
   ER binding BG1Luc In vivo 
   assay (n=19) ER TA uterotrophic  
    (n=16) assay (n=18)
BL1S1_1_11 LxxLL2 P78537 0.51 0.54 0.49
BRD8_254_276 LxxLL267 Q9H0E9 0.74 0.80 0.87
CBP_57_80 LxxLL70 Q92793 0.65 0.84 0.71
EP300_69_91 LxxLL81 Q09472 0.73 0.82 0.84
GNAQ_21_43 LxxLL34 P50148 0.80 0.81 0.86
HAIR_745_767_C755S/C759S LxxLL758 O43593 0.46 0.53 0.46
IKBB_277_299 LxxLL289 Q15653 0.80 0.78 0.82
JHD2C_2054_2076 LxxLL2066 Q15652 0.85 0.79 0.88
LCOR_40_62 LxxLL53 Q96JN0 0.64 0.84 0.81
MED1_591_614 LxxLL604 Q15648 0.69 0.80 0.81
MLL2_4175_4197 LxxLL4188 O14686 0.65 0.81 0.79
NCOA1_620_643 LxxLL633 Q15788 0.82 0.80 0.87
NCOA1_677_700 LxxLL690  0.87 0.76 0.89
NCOA1_737_759 LxxLL749  0.78 0.81 0.83
NCOA1_1421_1441 LxxLL1435  0.84 0.74 0.89
NCOA2_628_651 LxxLL641 Q15596 0.86 0.75 0.88
NCOA2_677_700 LxxLL690  0.84 0.80 0.87
NCOA2_733_755 LxxLL745  0.82 0.81 0.87
NCOA3_609_631 LxxLL621 Q9Y6Q9 0.79 0.82 0.85
NCOA3_609_631_C627S LxxLL621  0.86 0.78 0.89
NCOA3_673_695 LxxLL685  0.85 0.78 0.89
NCOA3_725_747 LxxLL738  0.85 0.78 0.89
NR0B1_1_23 LxxML13 P51843 0.78 0.81 0.82
NR0B1_136_159 LxxLL146  0.83 0.75 0.83
NR0B2_9_31_C9S/C11S LxxLL21 Q15466 0.82 0.76 0.84
NR0B2_106_128 LxxIL118  0.83 0.71 0.89
NR0B2_201_223_C207S LxxVL214  0.78 0.80 0.82
NRBF2_128_150 LxxLL141 Q96F24 0.64 0.77 0.66
NRIP1_120_142 LxxLL133 P48552 0.78 0.80 0.85
NRIP1_121_143_P124R LxxLL133  0.64 0.81 0.78
NRIP1_253_275_C263S LxxLL266  0.81 0.80 0.88
NRIP1_368_390 LxxLL380  0.84 0.73 0.84
NRIP1_488_510 LxxLL501  0.83 0.80 0.89
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In summary, the obtained results in this study with the 
SeRMs indicate that the coregulator binding assay based on the 
PamChip® plate is able to distinguish receptor agonists from 
antagonists. Moreover, in transcriptional activation assays, cell 
proliferation assays and the in vivo uterotrophic assay, the ef-
fects of eR antagonists generally are measured in combination 
with potent estrogens such as e2 or ee2, while in the coregu-
lator binding assay, the antagonist properties can be measured 
directly, i.e., without the addition of a potent eR agonist. How-
ever, although the in vivo antagonist effects of the SeRMs (e.g., 
tamoxifen, 4-hydroxytamoxifen and OMIY-bisphenol) could be 
predicted correctly, the coregulator binding assay is not able to 
reveal the eR agonist properties of these SeRMs. therefore, 
say (33 coactivators with R2	≥0.80,	n=19),	BG1Luc	ER	tran-
scriptional activation assay (32 coactivators with R2	 ≥0.80,	
n=16), and the in vivo uterotrophic assay (30 coactivators with 
R2	≥0.85,	n=18),	the	coregulator	binding	assay	demonstrated	
its usefulness in screening substances for in vitro eR agonistic 
activity. Moreover, 25 coactivators have been shown to bind 
to	endogenous	ERα	in	cell	lysates	and	in	breast	tumors	when	
tested on a PamChip® plate peptide microarray in the presence 
of e2 (Houtman et al., 2012). twenty-one of these 25 coacti-
vators (highlighted in tab. 2) also display a high correlation 
coefficient	with	the	estrogenicity	observed	in	the	uterotrophic	
assay, indicating the biological relevance of the correlation 
found with these coactivators. 
Coregulator binding assay Peptide IDa Motif  Uniprot Accession  Coefficient of determination (R2)
   ER binding BG1Luc In vivo 
   assay (n=19) ER TA uterotrophic  
    (n=16) assay (n=18)
NRIP1_700_722 LxxLL713  0.81 0.80 0.87
NRIP1_701_723 LxxLL713  0.81 0.81 0.88
NRIP1_805_831 LxxLL819  0.81 0.80 0.88
NRIP1_924_946 LxxLL936  0.80 0.82 0.87
NRIP1_924_946_C945S LxxLL936  0.84 0.80 0.88
NRIP1_1055_1077 LxxML1068  0.84 0.79 0.89
NSD1_894_916 FxxLL907 Q96L73 0.62 0.81 0.74
PELP1_20_42 LxxLL33 Q8IZL8 0.76 0.79 0.84
PELP1_168_190 LxxLL181  0.80 0.75 0.83
PELP1_446_468 LxxLL459  0.77 0.81 0.82
PELP1_571_593_C575S/C581S LxxLL584  0.83 0.71 0.84
PPRC1_151_173 LxxLL164 Q5VV67 0.77 0.80 0.88
PRGC1_130_155 LxxLL144 Q9UBK2 0.73 0.61 0.82
PRGC1_134_154 LxxLL144  0.80 0.72 0.80
PRGC2_146_166 LxxLL156 Q86YN6 0.85 0.74 0.88
PRGC2_338_358 LxxLL343  0.83 0.80 0.88
PROX1_57_79 LxxLL70 Q92786 0.80 0.82 0.87
TIF1A_747_769 LxxLL760 O15164 0.83 0.74 0.82
TIP60_476_498 LxxLL489 Q92993 0.78 0.82 0.84
TREF1_168_190 LxxLL181 Q96PN7 0.76 0.80 0.87
TRRAP_3535_3557_C3535S/C3555S LxxLL3548 Q9Y4A5 0.60 0.71 0.74
TRXR1_132_154 LxxLL145 Q16881 0.81 0.83 0.89
WIPI1_119_141 LxxLL132 Q5MNZ9 0.60 0.76 0.78
ZNHI3_89_111 LxxLL101 Q15649 0.82 0.80 0.88
a ID as follows: [coregulator]_[aa start]_[aa end of peptide],  bold coactivators have been shown previously to bind to endogenous  
ERα in cell lysates and in breast tumors in the presence of E2 (Houtman et al., 2012). 
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other types of in vitro assays, e.g., reporter gene assays and the 
H295R steroidogenesis assay, are needed to build a panel of in 
vitro assays to increase the predictive power and to reach a simi-
lar performance in qualifying compounds as that achieved by 
the in vivo uterotrophic assay. the present study thus shows that 
the coregulator binding assay is useful within such a panel of in 
vitro test systems for estrogenicity testing, allowing easy high-
throughput screening and prioritization of chemicals, thereby 
contributing to the reduction – and ultimately the replacement 
– of current animal testing for (anti-)estrogenic effects.
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